![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supplementary Information]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Information)
28kB |
| Item Type: | Article |
|---|---|
| Title: | Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue |
| Creators Name: | Liu, T., Dogan, I., Rothe, M., Kunz, J.V., Knauf, F., Gollasch, M., Luft, F.C. and Gollasch, B. |
| Abstract: | Cardiovascular disease is the leading cause of mortality in patients with renal failure. Red blood cells (RBCs) are potential reservoirs for epoxy fatty acids (oxylipins) that regulate cardiovascular function. Hemoglobin exhibits pseudo-lipoxygenase activity in vitro. We previously assessed the impact of single hemodialysis (HD) treatment on RBC epoxy fatty acids status in circulating arterial blood and found that eicosanoids in oxygenated RBCs could be particularly vulnerable in chronic kidney disease and hemodialysis. The purpose of the present study was to evaluate the differences of RBC epoxy fatty acids profiles in arterial and venous blood in vivo (AV differences) from patients treated by HD treatment. We collected arterial and venous blood samples in upper limbs from 12 end-stage renal disease (ESRD) patients (age 72±12 years) before and after HD treatment. We measured oxylipins derived from cytochrome P450 (CYP) monooxygenase and lipoxygenase (LOX)/CYP ω/(ω-1)-hydroxylase pathways in RBCs by LC-MS/MS tandem mass spectrometry. Our data demonstrate arteriovenous differences in LOX pathway metabolites in RBCs after dialysis, including numerous hydroxyeicosatetraenoic acids (HETEs), hydroxydocosahexaenoic acids (HDHAs) and hydroxyeicosapentaenoic acids (HEPEs). We detected more pronounced changes in free metabolites in RBCs after HD, as compared with the total RBC compartment. Hemodialysis treatment did not affect the majority of CYP and CYP ω/(ω-1)-hydroxylase products in RBCs. Our data indicate that erythro-metabolites of the LOX pathway are influenced by renal-replacement therapies, which could have deleterious effects in the circulation. |
| Keywords: | Hemodialysis, Eicosanoids, Lipidomics, Oxylipins, Erythrocyte, Arterio-venous, Biotransformation |
| Source: | Prostaglandins, Leukotrienes, and Essential Fatty Acids |
| ISSN: | 0952-3278 |
| Publisher: | Elsevier |
| Volume: | 181 |
| Page Range: | 102453 |
| Date: | June 2022 |
| Additional Information: | Erratum in: Prostaglandins Leukot Essent Fatty Acids 2022 Dec 6; 102521. [in Press] Copyright © 2022 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Official Publication: | https://doi.org/10.1016/j.plefa.2022.102453 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
